Search Results
Your search for ,twO matches 11972 pages
Showing 2651 - 2700Mount Sinai Health System and BronxCare Health System Open Comprehensive Cancer Facility
Mount Sinai Health System, together with BronxCare Health System, recently held a ribbon-cutting to launch BronxCare Mount Sinai Comprehensive Cancer Care—a new, state-of-the-art comprehensive cancer facility in the Bronx. The new spacewill allow both health systems to bring their strengths...
Margaret Foti, PhD, MD (hc), Honored With 2021 Tara Withington Public Service Award
The American Association for Cancer Research (AACR) recently congratulated its Chief Executive Officer, Margaret Foti, PhD, MD (hc), on her recognition by the Society for Immunotherapy of Cancer (SITC) with its 2021 Tara Withington Public Service Award. According to the SITC, this award “honors an ...
Asciminib for Philadelphia Chromosome–Positive Chronic Myeloid Leukemia
On October 29, 2021, the oral kinase inhibitor asciminib was granted accelerated approval for adults with Philadelphia chromosome–positive chronic myeloid leukemia (CML) in chronic phase previously treated with at least two tyrosine kinase inhibitors and regular approval for adults with...
Mammen Chandy, MD, FRACP, FRACPA: A Pioneer in India’s Bone Marrow Transplantation Services
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with bone marrow transplant expert Mammen Chandy, MD, FRACP, FRACPA, Director of Tata Medical Center, in Kolkata, India. Dr. Chandy was instrumental in establishing the first sustained bone marrow...
Mitchell D. Schnall, MD, PhD, Re-elected Group Co-Chair of the ECOG-ACRIN Cancer Research Group
The Principal investigator Committee of the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) re-elected Mitchell D. Schnall, MD, PhD, as the Group Co-Chair, a position he has held since the founding of the Group in 2012. Dr. Schnall will serve in this role from 2021 to 2031. Dr. Schnall co-leads the...
The History of Medical Oncology in Europe, 1955–1985
Our goal with this review of the pivotal years of oncology in Europe is to acknowledge the tremendous contributions of the early leaders in the field and to help young investigators learn from the past to better cope with the inevitable challenges of today and tomorrow. “On ne connaît pas...
COVID-19 Vaccine Requirements for Medicare, Medicaid Facilities, and Employers of 100 or More Staff Released
On November 4, 2021, the Centers for Medicare & Medicaid Services (CMS) issued an interim final rule requiring COVID-19 vaccination of eligible staff at health-care facilities that participate in the Medicare and Medicaid programs, and the Occupational Safety and Health Administration (OSHA)...
ASCO Releases New Guidelines on the Management of Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and CAR T-Cell Therapy
ASCO has released new recommendations for the management of adverse events related to two immunotherapy modalities with increasing application in cancer care—immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy. The recommendations were published as two separate...
Patients With Hormone Receptor–Positive Breast Cancer and Emergent ESR1 Mutations May Benefit From Early Switch to Fulvestrant/Palbociclib
Among patients with hormone receptor–positive breast cancer treated with an aromatase inhibitor plus palbociclib, those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to fulvestrant plus...
Jordan’s Queen Rania Presents King Hussein Awards for Cancer Research
Her Majesty Queen Rania Al Abdullah of Jordan honored recipients of the 2021 King Hussein Award for Cancer Research during ceremony held on November 14 by the King Hussein Cancer Foundation (KHCF). The event was conducted under the patronage of Their Majesties King Abdullah II and Queen Rania Al...
Increased Risk of Early Cardiac Toxicity With Posttransplantation Cyclophosphamide in Allogeneic HSCT
In a French single-center retrospective cohort study reported in JACC: CardioOncology, Rémy Duléry, MD, of Saint-Antoine Hospital, Paris, and colleagues found that posttransplantation cyclophosphamide was associated with a significantly increased risk of early cardiac toxicity among patients...
PHOEBE Trial: Pyrotinib/Capecitabine vs Lapatinib/Capecitabine for Previously Treated Patients With HER2-Positive Metastatic Breast Cancer
Among previously treated patients with HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had longer overall survival than those who received lapatinib plus capecitabine, according to updated results from the phase III PHOEBE trial presented by Binghe Xu, MD,...
Update on the Incidence of NSCLC: Focus on Need to Implement Widescale Screening
Recent articles in JAMA Oncology focused on lung cancer and screening strategies. Apar Kishor Ganti, MD, MS, of the University of Nebraska Medical Center, Omaha, and colleagues provided updated data on non–small cell lung cancer (NSCLC) incidence, prevalence, and stage through 2017.1 Sylvia K....
Expert Point of View: Nabil F. Saba, MD, FACP
“It’s becoming more and more clear that increasing the cytotoxic effect of treatment and expecting to get a better outcome is an approach of the past,” said Nabil F. Saba, MD, FACP, the Lynne and Howard Halpern Chair in Head and Neck Cancer Research, Professor and Vice Chair ofHematology and...
Radiation Therapy for HPV-Related Oropharyngeal Squamous Cell Carcinoma: Prospects and Controversies
In the treatment of patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma, neither cancer outcomes nor measurable quality of life have yet been shown to differ between surgery- and radiotherapy-based approaches, according to Sue S. Yom, MD, PhD, FASTRO, Professor of ...
Expert Point of View: Nabil F. Saba, MD, FACP
“Immunotherapy is now the standard of care in the recurrent metastatic setting,” said Nabil F. Saba, MD, FACP, Director of Head and Neck Oncology at Emory University and a specialist in immunotherapy for head and neck cancer. “However, we’re still struggling with the question of which immunotherapy ...
Society for Integrative Oncology Focuses on the Science of Living Well With Cancer
Guest Editor’s Note: With the easing of some COVID-19 restrictions, the Society for Integrative Oncology (SIO) held its 2021 international conference in a hybrid format. It focused on the science of living well with cancer, challenges in designing integrative oncology research, and the role of...
Establishing a Health Equity Report Card to Eradicate Disparities in Cancer Care
Although enormous progress over the past 50 years in every aspect of cancer care, including prevention, screening, chemotherapy, targeted therapy, surgery, radiation therapy, and supportive care, has resulted in increases in lives saved—from 3 million in 1971 to 16.9 million in 2019—the burden of...
Elacestrant May Improve Outcomes for Postmenopausal Patients With Progressive ER-Positive HER2-Negative Metastatic Breast Cancer
The investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine monotherapy in the second- or third-line setting for postmenopausal...
Elacestrant May Improve Outcomes for Postmenopausal Patients With Progressive ER-Positive HER2-Negative Metastatic Breast Cancer
The investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine therapy for postmenopausal patients with estrogen receptor...
Molecular Tumor Profiling May Improve Treatment Matching for Patients With Metastatic Breast Cancer
The use of multigene sequencing and SNP array as a therapeutic decision tool improved the outcomes of patients with metastatic breast cancer if the patients carried alterations classified in the I/II tiers of the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT), according to...
Study Examines Rates of Lymphedema in Black and White Patients With Breast Cancer
Black women had a 3.85-fold increased risk of developing lymphedema following treatment for breast cancer compared to White women, according to the results from a study by Barrio et al being presented at the 2021 San Antonio Breast Cancer Symposium (Abstract GS4-01). In addition, the researchers...
Poziotinib in Previously Treated Patients With NSCLC and HER2 Exon 20 Insertion Mutations
In a cohort of the phase II ZENITH20-2 trial reported in the Journal of Clinical Oncology, Le et al found that the tyrosine kinase inhibitor poziotinib produced responses in previously treated patients with non–small cell lung cancer (NSCLC) and HER2 exon 20 insertion mutations. Study Details In...
Fully Vaccinated Patients With Multiple Myeloma: Rates of SARS–CoV-2 Breakthrough Infection and Hospitalization
In a U.S. cohort study reported in JAMA Network Open, Wang et al found that fully vaccinated patients with multiple myeloma were at increased risk of breakthrough SARS–CoV-2 infection, and that those with breakthrough infection were more likely to be hospitalized vs fully vaccinated persons without ...
KEYNOTE-355 Final Analysis Reveals Survival Benefit With Pembrolizumab in Triple-Negative Breast Cancer
The final overall survival results from the KEYNOTE-355 study showed a statistically significant 27% reduction in the risk of death for patients with metastatic triple-negative breast cancer whose tumors were strongly positive for PD-L1, defined as a combined positive score (CPS) of at least 10 and ...
COVID-19 Vaccination: Patients With Multiple Myeloma May Lack T-Cell Response
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccination may also fail to mount a T-cell response, researchers from the Icahn School of Medicine at Mount Sinai have reported. This scenario seemed to be most common among patients actively treated with anti-CD38 and...
Evaluation of Carfilzomib-Based Induction, Consolidation, and Maintenance Strategies in Newly Diagnosed Multiple Myeloma
In the Italian phase II FORTE trial reported in The Lancet Oncology, Francesca Gay, PhD, and colleagues found that induction therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) produced a higher response rate vs carfilzomib, cyclophosphamide, and dexamethasone (KCd) among patients aged...
Vidutolimad Plus Pembrolizumab in PD-1 Refractory Melanoma
The addition of vidutolimod to pembrolizumab could help overcome resistance to immune checkpoint inhibition in patients with metastatic or unresectable cutaneous melanoma, according to data presented by John M. Kirkwood, MD, and colleagues at the Society for Immunotherapy of Cancer (SITC) 2021...
Sotigalimab Plus Nivolumab in Anti–PD-1/PD-L1–Refractory Melanoma
Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, but a significant number of patients still fail to respond to anti–PD-1 therapy. The novel combination of sotigalimab, an anti-CD40 monoclonal antibody, and the PD-1 inhibitor nivolumab could help address this...
Impact of Time of Day of Immune Checkpoint Inhibitor Infusion on Overall Survival in Advanced Melanoma
On this episode, we’ll hear about a study that examined the impact of the time of day that a patient with advanced melanoma receives an immune checkpoint inhibitor infusion on overall survival. Then, we’ll hear about two recent approvals from the FDA—one in relapsed or refractory multiple myeloma,...
FDA Approves Rituximab Plus Chemotherapy for Several Pediatric Hematologic Malignancies
On December 2, the U.S. Food and Drug Administration (FDA) approved rituximab (Rituxan) in combination with chemotherapy for pediatric patients (≥ 6 months to < 18 years old) with previously untreated, advanced-stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma,...
Keith T. Flaherty, MD, on Results From the DREAMseq Trial
Invited discussant of the phase III DREAMseq trial, Keith T. Flaherty, MD, said the findings still leave room for nuanced decision-making.1 Dr. Flaherty is Professor of Medicine at Harvard and Director of the Henri and Belinda Termeer Center for Targeted Therapy at the Massachusetts General...
DREAMseq Trial: In Advanced Melanoma With BRAF Mutations, Start With Immunotherapy
In the treatment of patients with advanced melanoma containing BRAF mutations, initial treatment with an immunotherapy combination achieved superior overall survival compared with targeted therapy in the phase III DREAMseq trial, also known as the ECOG-ACRIN EA6134 trial. The results were reported ...
Fosnetupitant vs Fosaprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting
In a Japanese phase III noninferiority trial (CONSOLE) reported in the Journal of Clinical Oncology, Hata et al found that fosnetupitant was noninferior to fosaprepitant in preventing nausea and vomiting in patients receiving highly emetogenic chemotherapy (both in combination with palonosetron and ...
Study Examines the Effect of Breast MRI on Short-Term Quality of Life in Women With DCIS
In a substudy of the ECOG-ACRIN E4112 cohort trial reported in JAMA Network Open, Fazeli et al found that approximately half of women with ductal carcinoma in situ (DCIS) undergoing magnetic resonance imaging (MRI) for pretreatment planning experienced fear or anxiety before and during the...
COG AAML1331 Trial: Arsenic Trioxide and All-Trans Retinoic Acid in Pediatric Patients With APL
As reported in JAMA Oncology by Kutny et al, the Children’s Oncology Group (COG) AAML1331 trial has shown that treatment with arsenic trioxide and all-trans retinoic acid (ATRA) with no maintenance therapy produced high event-free and overall survival rates in pediatric patients with acute...
Phase I Trial Investigates HER-Targeted CAR-M for HER2-Overexpressing Solid Tumors
HER2-targeted chimeric antigen receptor macrophages (CAR-M) could be the next cell therapies to treat advanced solid tumors overexpressing HER2, according to data presented by Kim A. Reiss, MD, and colleagues at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting (Abstract 951)....
Response to SARS–CoV-2 mRNA Vaccination in Patients With B-Cell Depletion Associated With CAR T-Cell Therapy
In a small single-institution study reported in a research letter in JAMA Oncology, Parvathaneni et al found that SARS–CoV-2 mRNA vaccination produced antibody responses in nearly half—and CD4 T-cell responses in more than half—of patients with B-cell depletion due to treatment with...
Cancer-Related Financial Toxicity: Role of Race
In a study reported in JCO Oncology Practice, Panzone et al found that compared to White patients with a history of cancer, Black patients and ‘other race’ patients—but not Hispanic patients—were significantly more likely to have experienced financial toxicity due to cancer. Study Details The...
Does Yoga Improve Quality of Life in Men With Prostate Cancer?
A diagnosis of prostate cancer may translate to approximately a 30% increase in the incidence of depression and anxiety, a fourfold higher risk of heart attack, and a twofold higher risk of suicide. A study published by Kaushik et al in Prostate Cancer and Prostatic Diseases aimed to evaluate the...
Phase II Breast Cancer Trial: Large Declines in Ki67 Index Seen With Oral Selective Estrogen Receptor Degrader
In the phase II coopERA Breast Cancer trial, which evaluated two endocrine neoadjuvant therapies in estrogen receptor–positive, HER2-negative early breast cancer, the oral selective estrogen receptor degrader giredestrant led to a greater reduction in Ki67 level—a measure of cancer cell...
Addressing the Global Challenges of Cancer Prevention and Treatment
Nearly 20 million people around the world were diagnosed with cancer in 2020, with 10 million losing their lives to this devastating disease. We highlight here the salient points from our article published in CA: A Cancer Journal for Clinicians,1 which describes the major themes and...
FDA Approves Maribavir for Posttransplant CMV
On November 23, the U.S. Food and Drug Administration (FDA) approved the antiviral maribavir (Livtencity) for adult and pediatric patients aged 12 years and older (and weighing at least 35 kg) with posttransplant cytomegalovirus (CMV) infection or disease that is not responsive (with or without...
Shiitake Mushroom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on shiitake mushroom ...
Passionate About Surgical Oncology, Masakazu Toi, MD, PhD, Is a Leader in Japanese Clinical Trials
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Masakazu Toi, MD, PhD, a clinical breast cancer expert who is keen on research that translates basic science into clinical study. He is involved in various innovative research projects on the development ...
Maintenance Daratumumab After Initial Therapy for Transplant-Eligible Multiple Myeloma: More Questions Than Answers From CASSIOPEIA Part 2
Bortezomib, thalidomide, and dexamethasone (VTd) is an acceptable, effective standard-of-care induction treatment in Europe for patients with newly diagnosed myeloma who are eligible for autologous stem cell transplantation. CASSIOPEIA is a two-part, open-label, randomized, phase III trial in...
Maintenance Daratumumab Prolongs Progression-Free Survival in Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Philippe Moreau, MD, of the University Hospital Hôtel-Dieu, Nantes, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has showed significantly prolonged progression-free survival with maintenance daratumumab vs observation...
The Role of Spirituality in Palliative Care
National surveys consistently show that spirituality and religion are important components in the lives of most Americans, with more than 90% of adults expressing a belief in God and more than 70% identifying religion as one of the most important influences in their lives.1 Studies also show that...
Five Percent Overall Medicare Reimbursement Cut Estimated for Medical Oncology in 2022
On November 2, 2021, the Centers for Medicare & Medicaid Services (CMS) released the 2022 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) final rule. Although ASCO will analyze the rule in greater detail in the coming days, initial highlights from the rule are outlined...
COVID-19 Resources for People With Cancer
ASCO has compiled a number of resources to help people with cancer navigate COVID-19. Coronavirus and COVID-19: What People With Cancer Need to Know Cases of COVID-19 have arisen all over the world. Here’s what people with cancer and cancer survivors need to know about the disease. Available at...
